• AZD1390: ATM Kinase Inhibitor Workflows for Cancer Research

  2026-07-14

  AZD1390 unlocks new precision in DNA double-strand break repair studies and radiosensitization workflows, particularly for glioma and lung cancer models. This guide translates the latest mechanistic insights and experimental protocols into actionable steps for researchers leveraging this selective ATM kinase inhibitor.

• 12-O-tetradecanoyl phorbol-13-acetate: Mechanistic and Resea

  2026-07-14

  12-O-tetradecanoyl phorbol-13-acetate (TPA) is a potent activator of the ERK/MAPK pathway via protein kinase C signaling. TPA provides reproducible, quantitative induction of ERK phosphorylation in diverse cell types, and is widely used in skin cancer models and signal transduction research. This article presents mechanistic detail, evidence, and workflow integration for the use of TPA in advanced biomedical studies.

• AZD1480: Precision JAK2 Inhibitor for STAT3 Pathway Research

  2026-07-13

  AZD1480 stands out as a highly selective JAK2 inhibitor, empowering cancer researchers to dissect JAK2/STAT3-driven proliferation, angiogenesis, and immune evasion. Its robust performance in both myeloma and solid tumor models, along with proven synergy in combination therapies, positions AZD1480 as a versatile tool for translational oncology studies.

• 25-Hydroxycholesterol Drives AMPK Activation in Tumor Macrop

  2026-07-13

  Xiao et al. (2024) delineate a novel immunometabolic mechanism in which lysosome-accumulated 25-hydroxycholesterol (25HC) activates AMPKα via the GPR155-mTORC1 axis, reprogramming tumor-associated macrophages (TAMs) toward an immunosuppressive phenotype. These findings reveal new strategies for modulating macrophage function to enhance anti-tumor immunity and improve checkpoint blockade efficacy.

• AZD1480 as a Precision Tool for Unraveling JAK2/STAT3 in Tum

  2026-07-12

  Explore how AZD1480, a potent JAK2 inhibitor, uniquely enables the dissection of JAK2/STAT3 signaling in the context of tumor immune escape and therapeutic resistance. This article delivers a deeper, translational perspective on leveraging AZD1480 to guide experimental design and combination strategies in cancer research.

• InstaBlue Protein Stain Solution: Precision Protein Visualiz

  2026-07-10

  Explore how InstaBlue Protein Stain Solution empowers high-sensitivity protein analysis in neurodegenerative and molecular pathology workflows. This in-depth review reveals its scientific advantages over traditional stains and its impact on biomedical research, drawing on recent spatial transcriptomics findings.

• AZD0156: Selective ATM Kinase Inhibitor for DNA Damage Respo

  2026-07-09

  AZD0156 is a potent and selective ATM kinase inhibitor that enhances DNA damage response modulation in cancer therapy research. Its high specificity, oral bioavailability, and strong evidence base support its use in preclinical and clinical workflows. This article details key mechanisms, benchmarks, and practical integration for researchers.

• Angiotensin II: Applied Workflows for Vascular Remodeling Re

  2026-07-09

  APExBIO’s Angiotensin II (Asp-Arg-Val-Tyr-Ile-His-Pro-Phe) sets the benchmark for modeling hypertension, vascular smooth muscle cell hypertrophy, and abdominal aortic aneurysm pathogenesis. This guide translates advanced experimental workflows and troubleshooting strategies into practical, reproducible protocols for cardiovascular disease investigation.

• ISRIB (trans-isomer): From ISR Modulation to Memory Preserva

  2026-07-08

  Discover how ISRIB (trans-isomer), a leading PERK inhibitor, uniquely enables researchers to dissect the integrated stress response’s role in memory and disease. This article explores recent breakthroughs in cognitive memory enhancement and experimental design.

• Refining In Vitro Drug Response Metrics in Cancer Evaluation

  2026-07-08

  Schwartz's dissertation advances the evaluation of anti-cancer agents by dissecting the relationship between growth inhibition and cell death in vitro. The work proposes refined measurement strategies, improving mechanistic insight and translational relevance for drug screening.

• AZD0156: ATM Kinase Inhibitor Workflows for Cancer Research

  2026-07-07

  AZD0156 sets a new benchmark for selective ATM kinase inhibition, transforming how researchers dissect DNA damage response and checkpoint control in cancer models. Discover advanced protocols, troubleshooting insights, and translational strategies to unlock the full potential of this potent DNA damage response inhibitor.

• Targeting p16: Antibody Fragment-Drug Conjugates in Cancer T

  2026-07-07

  This study introduces a novel antibody fragment-drug conjugate (AFDC) that targets p16, a cell cycle regulator overexpressed in several aggressive cancers. The innovation lies in using a humanized single-chain antibody fragment fused with a cell-penetrating peptide to selectively deliver cytotoxic drugs to p16-high cancer cells, demonstrating strong in vitro antitumor activity and highlighting a new direction for targeted therapy.

• Streptozotocin for Experimental Diabetes: Protocols & Insigh

  2026-07-06

  Streptozotocin (STZ) is the gold standard for reproducible β-cell apoptosis induction and experimental diabetes mellitus modeling. This guide translates the latest research and troubleshooting strategies into actionable workflows, empowering diabetes researchers to optimize outcomes and explore neuroimmune complications with precision.

• AZD0156: ATM Kinase Inhibitor Workflows for Cancer Therapy R

  2026-07-06

  AZD0156 empowers researchers to precisely modulate DNA damage response and checkpoint control in cancer models, with proven synergy in HR-proficient ovarian cancer. This article delivers hands-on workflow guidance, troubleshooting insights, and data-driven protocol optimization for selective ATM kinase inhibitor studies.

• Mechanism-Based Discovery of TB DHFR Inhibitors via HTS Inte

  2026-07-05

  Santa Maria et al. present an innovative framework that integrates high-throughput biophysical profiling with machine learning to elucidate mechanisms of action and identify new inhibitors of Mycobacterium tuberculosis dihydrofolate reductase (Mtb DHFR). This approach bridges phenotypic and target-based screening, accelerating the identification of antibacterial agents with defined molecular targets.

15370 records 1/1025 page Next 12345 下5页 Last page